T Cell Sciences deal

Phase I studies of the drug began in late 1992 in burn victims at risk of developing adult respiratory distress syndrome, but patient accrual has been slow.

Under the prior agreement, TCEL had responsibility for pre-clinical development, which was funded by SmithKline. SmithKline paid for $12 million of pre-clinical development costs. ...